- Previous Close
0.00 - Open
19.20 - Bid 15.35 x 40700
- Ask 17.35 x 39400
- Day's Range
19.20 - 19.20 - 52 Week Range
16.56 - 20.50 - Volume
500 - Avg. Volume
14 - Market Cap (intraday)
4.538B - Beta (5Y Monthly) 1.39
- PE Ratio (TTM)
107.50 - EPS (TTM)
0.18 - Earnings Date May 7, 2025
- Forward Dividend & Yield 0.05 (0.28%)
- Ex-Dividend Date Dec 5, 2024
- 1y Target Est
--
Ambu A/S, a medical technology company, develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, and displaying units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products; airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, resuscitators, video laryngoscopes, and training manikins. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.
www.ambu.comRecent News: AMBFF
View MorePerformance Overview: AMBFF
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMBFF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMBFF
View MoreValuation Measures
Market Cap
4.54B
Enterprise Value
4.53B
Trailing P/E
110.29
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.34
Price/Book (mrq)
6.13
Enterprise Value/Revenue
5.55
Enterprise Value/EBITDA
39.13
Financial Highlights
Profitability and Income Statement
Profit Margin
5.77%
Return on Assets (ttm)
6.70%
Return on Equity (ttm)
5.81%
Revenue (ttm)
5.65B
Net Income Avi to Common (ttm)
326M
Diluted EPS (ttm)
0.18
Balance Sheet and Cash Flow
Total Cash (mrq)
588M
Total Debt/Equity (mrq)
9.73%
Levered Free Cash Flow (ttm)
264.75M